A Declaration from Members of the World's Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders – healthcare providers, governments, multilateral organizations, and non-governmental donor organizations – to ensure that COVID vaccines and treatments get to the patients in the world who most need them. We are working hard to fulfill this responsibility.

- Our sector must continue to play a constructive, proactive part in developing COVID solutions and the global manufacturing capacity to produce them. In the past year, over 950 global R&D projects have been launched on COVID vaccines, treatments, and biologics, as companies have diverted efforts from other projectsⁱ. 70 percent of these projects are by small and medium sized companiesⁱⁱ. Over 250 global partnerships have been formed to build manufacturing capacityⁱⁱⁱ. And we are working hard to do more.
- Intellectual property is the foundation of our sector. It is responsible for creating the global biotech network that responded so quickly to the COVID crisis in the first place. It is what gives investors the confidence to fund companies with long time horizons and high risks. It gave companies the assurance that they could quickly pivot during the early days of the pandemic into COVID projects. And it helped ensure the type of global cooperation and partnerships that are driving companies, countries, and manufacturers to quickly scale up the production.
- We support strong, collaborative efforts like those endorsed by the G-20^{iv} to address the global imbalances in access to COVID vaccines and treatments. Success will require national governments to address legislative or contractual impediments to supplying populations in need, especially in low- and middle- income countries. Bottlenecks and shortages in global supply chains for vaccine production need to be urgently addressed. And strained health-care systems in low-and middle-income countries need significant support to ensure vaccines get to people.
- The proposed "waiver" of intellectual property rights proposed in the World Trade Organization (WTO) will be ineffective and counterproductive in addressing this crisis. Intellectual property rights are *not* responsible for the imbalance in COVID vaccine supplies between higher and lower income countries. It will create a long contentious global negotiation that will not urgently address the crisis, and foster more "vaccine nationalism," exacerbating shortages in an already strained global supply chain. It would divert limited resources from companies that are focused on maximizing current global partnerships while maintaining quality and patient safety. Lastly, it would send a powerful signal to the biotech sector and investors to avoid taking the risks to develop solutions in future public health emergencies.
- Current estimates are that existing global vaccine manufacturers will produce more than 11 billion doses of COVID vaccines in 2021^v, and significantly more in the first part of 2022. We are committed to working with other global stakeholders to see that these doses get to those that most need them, wherever they may be.

Company Signatories

United States of America

Alabama

Kanti Sunkavalli, CEO, Agile Biodetection Karim Budhwani, CEO, CerFlux, Inc. Deborah Bidanset, COO, SunFire Biotechnologies LLC John Bowman, CEO, Sure Med Compliance

California

Sam Alworth, CEO, AcuraStem Marilyn Bruno, CEO, Aequor, Inc.

Robert Bradway, CEO, Amgen

Gail Maderis, President & CEO, Antiva Biosciences, Inc.

Frank Watanabe, President & CEO, Arcutis Biotherapeutics

Michael Raab, President & CEO, Ardelyx

James Mackay, President & CEO, Aristea Therapeutics

Jeffrey Cleland, CEO, Ashvattha Therapeutics, Inc

Wilson Xu, CEO, Balto Pharmaceuticals, Inc.

Niguette Hunt, CEO, Candesant Biomedical

Rachel Haurwitz, President & CEO, Caribou Biosciences, Inc.

Michael Narachi, President & CEO, CODA Biotherapeutics

John Nicols, President & CEO, Codexis, Inc

Sujal Shah, CEO, CymaBay Therapeutics

Ryan Beal, CEO, Dyve Biosciences

Luis Pena, President & CEO, Evommune, Inc.

Michael Morrissey, President & CEO, Exelixis

Alexander Hardy, CEO, Genentech

Ted Love, CEO, Global Blood Therapeutics

Francisco LePort, CEO, Gordian Biotechnology

Robert Bernard, CEO, Ichor Medical Systems, Ins

Grace Colon, CEO & President, InCarda Therapeutics

Brett Monia, CEO, Ionis

Michael Miille, CEO, Joyn Bio

Rohit Shukla, CEO, Larta

Guy Iannuzzi, CEO, Mentus

Howard Robin, CEO, Nektar Therapeutics

Paul Hastings, President & CEO, Nkarta Therapeutics

Francis Parnell, Chairman & CEO, Parnell Pharmaceuticals, Inc.

Jennifer Cheng, President & CEO, PTM Therapeutics, Inc.

Paul Mola, President & CEO, Roswell Biotechnologies Inc.

Rosemarie Christopher, President, RxRS CRO

Brian Neman, CEO, Sanguine BioSciences, INC.

Larry Stambaugh, Chairman & CEO, Sarmal, Inc.

Craig Parker, CEO, Surrozen, Inc

William Newell, CEO, Sutro Biopharma, Inc.

David Webb, CEO, Synbal, Inc.

Oliver Fetzer, CEO, Synthetic Genomics

Sen Sundaram, CEO, Terns Pharmaceuticals, Inc.

Rick Winningham, CEO, Theravance BioPharma

Eric Dube, President & CEO, Travere Therapeutics Bonnie Anderson, Executive Chairwoman, Veracyte, Inc. George Scangos, CEO, Vir Biotechnology Keith Murphy, CEO, Viscient Biosciences

Colorado

Ron Lowy, Executive Chairman, PharmaJet

Connecticut

Jeff Kindler, CEO, Centrexion Therapeutics Erika Smith, CEO, ReNetX Bio

Delaware

Hervé Hoppenot, CEO, Incyte

Florida

Susan Washer, President & CEO, AGTC John Crowley, Chairman & CEO, Amicus Therapeutics Marc Thibonnnier, Founder & President, AptamiR Therapeutics, Inc. James Sapirstein, President & CEO, Azurrx Biopharma

Georgia

Ajay Houde, Co-Founder & CEO, Annoviant, LLC (F/K/A TGen Tech, LLC) Steven Damon, CEO, Micron Biomedical

Illinois

Richard Gonzalez, Chairman of the Board & CEO, AbbVie

Indiana

David Ricks, Chairman & CEO, Eli Lilly and Company

Massachusetts

Habib Dable, President & CEO, Acceleron Pharma Jackie Fouse, CEO, Agios Pharmaceuticals John Butler, President & CEO, Akebia Therapeutics Ludwig Hantson, CEO, Alexion Pharmaceuticals, Inc. Richard Pops, Chairman & CEO, Alkermes John Maraganore, CEO, Alnylam Pharmaceuticals Sylvia Wulf, President & CEO, AquaBounty Technologies, Inc. Tim Van Hauwermeiren, CEO & Co-Founder, argenx Alicia Secor, CEO, Atalanta Therapeutics John Oyler, Co-Founder, Chairman, & CEO, BeiGene Michel Vounatsos, CEO, Biogen Inc.

Nick Leschly, CEO, bluebird bio

Melissa Bradford-Klug, President, Citrine Medicine Ranjeet Banerjee, CEO, Cold Chain Technologies

Laurence Reid, CEO, Decibel Therapeutics

David Lucchino, CEO, Frequency Therapeutics

Chip Clark, President & CEO, Genocea Biosciences, Inc.

Jeff Livingstone, CEO, Igia Pharmaceuticals

Mark Enyedy, President & CEO, ImmunoGen

Adelene Perkins, CEO & Chair, Infinity Pharmaceuticals

Richard Paulson, President & CEO, Karyopharm

Louis Arcudi, CEO, Millendo

Stephane Bancel, CEO, Moderna

Stephen Yoder, President & CEO, Pieris Pharmaceuticals

Pablo Cagnoni, CEO, Rubius Therapeutics

Rogerio Vivaldi, President & CEO, Sigilon Therapeutics

Tony Loebel, President & CEO, Sunovion

Nancy Simonian, CEO, Syros Pharmaceuticals

Marc Casper, Chairman, President & CEO, Thermo Fisher Scientific Inc.

David Hoey, CEO, Vaxxas Inc.

Jeff Baxter, President & CEO, VBI Vaccines

Reshma Kewalramani, CEO & President, Vertex Pharmaceuticals Inc.

Paula Ragan, CEO, X4 Pharmaceuticals Inc.

Chris Garabedian, Chairman & CEO, Xontogeny

Maryland

Robert G. Kramer, President & CEO, Emergent BioSolutions

Rachel King, CEO, GlycoMimetics, Inc.

Scott Koenig, President & CEO, MacroGenics, Inc.

Stanley Erck, President & CEO, Novavax, Inc.

Oliver Schacht, President & CEO, OpGen Inc.

Ken Mills, President & CEO, REGENXBIO Inc.

Michigan

Mina Sooch, CEO, Ocuphire Pharma

Minnesota

Mark Platt, President & CEO, Recombinetics, Inc.

Arkadiusz Dudek, CEO, TTC Oncology

North Carolina

Arthur Alfaro, CEO & Director, 21MedTech

John Temperato, President & CEO, 9 Meters Biopharma

Jerzy Szewczyk, CEO, BioKier Inc.

Damian Shea, President, Statera Environmental Inc.

Anna Rath, CEO, Vestaron

Jian Bao, Co-Founder & CEO, ZY Therapeutics Inc.

Jason Zhou, CEO, Zymeron Corporation

New Jersey

Giovanni Caforio, CEO, Bristol Myers Squibb

Ivan Cheung, Chairman, Eisai Inc.

Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Mark Trudeau, President & CEO, Mallinckrodt Pharmaceuticals

Kenneth C. Frazier, CEO, Merck

Alex Martin, CEO, Palladio Biosciences

Stuart Peltz, CEO, PTC Therapeutics

New Mexico

Robert Curtis, President & CEO, Respira Therapeutics, Inc.

New York

Ron Cohen, President & CEO, Acorda Therapeutics, Inc. Chandrabali Ghose-Paul, CEO, Bioharmony Therapeutics Jeremy Levin, CEO, Ovid Therapeutics Albert Bourla, CEO, Pfizer Phil Gomez, CEO, SIGA Technologies, Inc. Kaspar Baenziger, CEO, Spicona Rashida Karmali, CEO, Tactical Therapeutics Inc.

Oklahoma

Colin Cumming, CEO, SensiQ

Pennsylvania

Wei He, Inventor, Founder & CEO, DTRM Biopharma Briggs Morrison, CEO, Syndax Carrie Bourdow, President & CEO, Trevena, Inc. Albert Gianchetti, President & CEO, XyloCor Therapeutics

South Carolina

Richard Alberti, Chief Operating Officer, Medpoint Lou Kennedy, CEO, Nephron Pharmaceuticals David Stefanich, CEO, RYMEDI inc. Shawn Regan, CEO, Rhythmlink International, LLC Cephus Simmons, Founder/CEO, SealCath, LLC Bruce Johnson, CEO, Stomagienics, Inc. Shea Harrelson, Co-Founder, Vikor Scientific John Carrington, CEO, ZVerse Scott Pancoast, CEO & Founder, Zylö Therapeutics Inc.

South Dakota

Eddie Sullivan, President & CEO, SAB Biotherapeutics, Inc.

Texas

Linnea Fletcher, Executive Director, InnovATEBIO

Utah

Myles Greenberg, President & CEO, Alucent Biomedical Inc. Rob Etherington, CEO, Clene, Inc. Flagg Flanagan, CEO & Chairman of the Board, DiscGenics, Inc.

Virginia

David Kalergis, CEO, Atelerix Life Sciences Inc.

Washington

Bradford Zakes, President & CEO, Cerevast Medical, Inc. Eric Dobmeier, President & CEO, Chinook Therapeutics Steve Harr, CEO, Sana Biotechnologies

Wisconsin

David Kettner, President, Virent

United Kingdom

Iraj Ali, CEO, Achilles Therapeutics

Claire Thompson, CEO, Agility Life Sciences

David Miles, CEO, AKL Research and Development

Richard Waterfield, CEO, AngioDesign

Ross Breckenridge, CEO, Arjuna Therapeutics

David Reynolds, CEO, AstronauTx

Kevin Lee, CEO, Bicycle Therapeutics

Erik Miljan, CEO, BioDivide Limited

Alison Clayton, CEO, Biogelx

Stefan Ogrodzinski, CEO, BioStatus Group

Matthew Durdy, CEO, Cell and Gene Therapy Catapult

Will West, CEO, CellCentric

Euan Cameron, CEO, Cohesion Medical Ltd

Carolyn Porter, CEO, CytoSeek

Mark Warne, CEO, DeepMatter Group

Martin Whitaker, CEO, Diurnal Group

Anthony Finbow, CEO, Eagle Genomics

David Hipkiss, CEO, Enesi Pharma Limited

Tim Wilson, CEO, Epsilogen Ltd

Werner Lanthaler, CEO, Evotec

Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies

Bernard Gilly, CEO, GenSight Biologics

Peter Jackson, CEO, INFEX Therapeutics

Ian Fotheringham, CEO, Ingenza

Wayne Channon, CEO, iosBio

Simon Saxby, CEO, Leaf Expression Systems

David Reynolds, CEO, LoQus23 Therapeutics

Ian Abercrombie, CEO, Medannex

Barry Sharples, CEO, Micregen

Darrin M Disley, CEO, Mogrify

Deborah ONeil, CEO, NovaBiotics

Rosamond Deegan, CEO, OMass Therapeutics

Henrik Hagemann, CEO, Puraffinity

Lisa Anson, CEO, Redx Pharma

Pieter-Willem Histsma Mulier, CEO, RevoluGen

Cliff Holloway, CEO, Scancell Holdings

Greg Madison, CEO, Shield Therapeutics

Malcolm Weir, CEO, Sosei Heptares

Charlotte Casebourne, CEO, Theolytics

Jonny Ohlson, CEO, Touchlight Genetics Ltd

Malcolm Boyce, CEO, Trio Medicines Limited

Bill Enright, CEO, Vaccitech Ltd

Suzanne Dilly, CEO, ValiRx

Netherlands

Michiel Lodder, CEO, 20Med Therapeutics Pieter Gaillard, CEO, 2-BBB Medicines BV Bas Reichert, CEO, BaseClear BV Herman Steen, CEO, BiOrion Technologies BV Bertus Quint, CEO & Founder, DEBx Medical BV Jos Lunenberg, CEO, ENPICOM BV Onno van de Stolpe, CEO, Galapagos Jan van de Winkel, CEO, Genmab A/S Roel Schaapveld, CEO, InteRNA Technologies B.V. Remko van Leeuwen, CEO, Madam Therapeutics Jos Joore, CEO, MIMETAS B.V. Sijmen de Vries, President & CEO, Pharming Group NV Bernd van Buuren, CEO, Protinhi B.V. van de Sande, CEO, Synaffix B.V. Hans Preusting, CEO, Synerkine Pharma Erik van den Berg, CEO, AM-Pharma Rob Meijer, CEO, Amphera BV Aram Krol, CEO, Euretos Troels Jordansen, CEO, Glycostem Therapeutics B.V. Marco de Boer, CEO, NTrans Technologies BV Katrien Reynders, CEO, Pan Cancer T Han van 't Klooster, CEO, PHarmaCytics Willemijn Vader, CEO, VitroScan B.V.

Switzerland

Carlo Bertozzi, CEO, Acthera Therapeutic
Werner Tschollar, CEO, AMYRA Biotech AG
Marc Gitzinger, CEO, BioVersys AG
Michael Bauer, CEO, Cellestia
Lorenzo Bosisio, CEO, EffRx Pharmaceuticals
Anne Schmidt, CEO, Elthera AG
Filippo Riva, Managing Director, Humabs BioMed SA
Jean-Paul Clozel, CEO, Idorsia
Alcide Barberis, CEO, Mabylon AG
Miro Venturi, CEO, Sintetica
Klaas Zuideveld, CEO, Versameb

Germany

Sebastian Guth, Head of the Americas, Bayer Jean-Michel Boers, President & CEO, USA, Boehringer Ingelheim Antje Roetger, CEO, Carpegen GmbH Johannes Bacher, Managing Director, Co-Founder, Curetis GmbH Klaus Afflerbach, CEO, Navigo Proteins

Australia

Geoff Daly, CEO, Analytica Ltd
Paul Perreault, Managing Director & CEO, CSL Behring

Canada

Russell Mcallister, CEO, Bold Therapeutics Inc. Sanj Singh, CEO, Temple Therapeutics

Denmark

Preben Bruun-Nyzell, CEO, 2N Pharma Lars Fruergaard Jørgensen, CEO, Novo Nordisk

France

David Loew, CEO, Ipsen Pharma SAS Paul Hudson, CEO, Sanofi

Italy

Alessandro Sidoli, CEO, Axxam SpA Lucio Rovati, CEO & Chief Scientific Officer, Rottapharm Biotech

Japan

Osamu Okuda, CEO & President, Chugai Pharmaceutical Co., Ltd. Christophe Weber, CEO, Takeda Pharmaceuticals

Lithuania

Arnas Karuzas, CEO, Ligence Rimantas Tuskevicius, CEO, SatiMed

Ireland

Bruce Cozadd, Chairman & CEO, Jazz Pharmaceuticals

Israel

Oren Glanz, CEO, Lempo Therapeutics

Portugal

Simão Soares, CEO & Co-Founder, SilicoLife

Spain

Luis Mora Capitan, Managing Director, Pharma Mar

Supporting Biotechnology Associations

Michelle McMurry-Heath, President & CEO, BIO

Steve Bates, Chair, International Council of Biotechnology Associations and CEO, UK BioIndustry Association

Lorraine Chiroiu, CEO, AusBiotech

Andrew Casey, President & CEO, BIOTECanada

Patricia Trinler, President, CR biomed

Claire Skentelbery, Director General, EuropaBio

Franck Mouthon, Chairman, France Biotech

Viola Bronsema, CEO, Secretary General, Bio Deutschland

Ricardo Gent, Executive Director, German Association of Biotechnology Industries

Matt Moran, Director, BioPharmaChem Ireland

Riccardo Palmisano, President, Federchimica Assobiotec

Osamu Nagayama, President, Japan Bioindustry Association

Annemiek Verkamman, Managing Director, HollandBIO

Simão Soares, CEO & President, P-BIO

Ion Arocena, CEO, AseBio (Spanish Bioindustry Association)

Helena Strigård, Director General, SwedenBIO

Michael Altorfer, CEO, Swiss Biotech Association

Wallace Lin, President, Taiwan Bio Industry Organization

Rachel Lane, Executive Director, BIO Alabama

Joan Koerber-Walker, President & CEO, Arizona Bioindustry Association, Inc. (AZBio)

Joe Panetta, President & CEO, Biocom California

Mike Guerra, President & CEO, California Life Sciences

Ahmed Enany, President, Southern California Biomedical Council (SoCalBio)

Jennifer Paton, President & CEO, Colorado BioScience Association

Michael Fleming, President, Delaware BioScience Association

Jessica Hyland, Executive Director, Iowa Biotechnology Association

John Conrad, President & CEO, Illinois Biotechnology Innovation Organization

Kristin Jones, President & CEO, Indiana Health Industry Forum

Kendalle Burlin O'Connell, President & COO, MassBio

Stephen Rapundalo, President & CEO, Michigan Biosciences Industry Association (MichBio)

Kelly Gillespie, President & CEO, Missouri Biotechnology Association

Rob Owen, Executive Director, Bio Nebraska

Debbie Hart, President & CEO, BioNJ

Greg Byrnes, Executive Director, NMBio

Jennifer Hawks Bland, CEO, NewYorkBIO

Erin Ford, Interim President & CEO, South Carolina BIO (SCBIO)

Abby Trotter, Executive Director, Life Science TN

Tom Kowalski, President & CEO, Texas Healthcare and Bioscience Institute (THBI)

Leslie Alexandre, President & CEO, Life Science Washington

Laura Gunter, Interim CEO, NCBio

Ivan Lugo, Executive Director, INDUNIV Research Center, Inc.

Robb Stoddard, President & CEO, BioAlberta

Meaghan Seagrave, Executive Director, BioNB

Jason Field, President & CEO, Life Sciences Ontario

Rory Francis, CEO, Prince Edward Island BioAlliance

Endnotes

ⁱ Biotechnology Innovation Organization, **COVID -19 Biotracker**, https://www.bio.org/policy/human-health/vaccines-biodefense/coronavirus/pipeline-trackerink

iii List of Global Vaccine Partnerships, https://www.bio.org/sites/default/files/2021-05/Industry_Partnerships_on_COVID_BIO.pdf

ii Ibid.

iv https://global-health-summit.europa.eu/rome-declaration_en

v https://www.bio.org/sites/default/files/2021-05/Airfinity_production.pdf